We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amid deadlock on negotiations between multinational drug firms and the Brazilian government over the possible compulsory licensing of key HIV/AIDS treatments, some leading firms could scale down plans to invest in local manufacturing.
Catalyst Biosciences, Inc. and Torrey Pines Institute for Molecular Studies announced today that they have entered into an exclusive worldwide license agreement for Catalyst's use of the Institute's seminal intellectual property covering protease engineering, selection and optimization.
Evotec AG and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company , today announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP.
P.P. Luxco Holdings II s.a.r.l., a wholly-owned subsidiary of Picchio Pharma Inc., announced today that it has exercised a warrant to acquire an additional 2,800,000 common shares of Neurochem Inc., representing approximately 7.5% of the issued and outstanding common shares of Neurochem Inc. after giving effect to the exercise of the warrant.
Belgian biopharma company UCB (UCBBt.BR: Quote, Profile, Research) said on Monday that European regulators had approved its plans to designate its brivaracetam epilepsy drug as a medicine to treat rare life-threatening conditions.
Harbin Pharmaceutical Group Co. (600664.SH), a unit of a major pharmaceutical company in China, said it plans to issue CNY1 billion in 365-day bills. The bills will be issued through the interbank market, the company said in a statement over the weekend.
An influential US foreign policy group, the Council on Foreign Relations, has highlighted the potential security problems posed by the advancing threat of HIV/AIDS in low-income countries.